Ocugen Completes Dosing in Phase 2/3 Stargardt Trial
MALVERN, Pa., USA — April 1, 2026 Ocugen, Inc. has announced the early completion of dosing in its Phase...
Stargardt disease
Advertisement
Phase 1 Gene Therapy Data Shows Promise in Stargardt Disease
MALVERN, Pa., January 12, 2026 — Ocugen, Inc. announced the peer-reviewed publication of positive Phase 1 GARDian1 clinical trial...
Tinlarebant Phase 3 Trial Marks Major Breakthrough for STGD1
San Diego, December 1, 2025 — Belite Bio has announced positive topline results from the pivotal global Phase 3...
AAVantgarde Secures $141 Million Series B to Advance Gene Therapies for Retinal Diseases
LONDON/MILAN, Nov. 3, 2025 — AAVantgarde Bio has raised $141 million in a Series B financing round, co-led by...
FDA Grants ODD and UK CTA Clears Gene Therapy for Stargardt
MILAN, Italy, Oct. 2, 2025 — AAVantgarde Bio announced that its investigational gene therapy AAVB-039 has received Orphan Drug...
Advertisement
